Integra LifeSciences (NASDAQ:IART) Issues FY 2026 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 2.400-2.500 for the period, compared to the consensus EPS estimate of 2.350. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Integra LifeSciences also updated its Q2 2026 guidance to 0.440-0.520 EPS.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Wells Fargo & Company upgraded Integra LifeSciences to a “hold” rating in a research report on Wednesday, March 18th. Argus reissued a “hold” rating on shares of Integra LifeSciences in a research note on Wednesday, April 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Friday, March 27th. Citigroup cut their target price on shares of Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating on the stock in a research note on Wednesday, March 11th. Finally, Wall Street Zen lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. One analyst has rated the stock with a Buy rating, three have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $14.20.

Integra LifeSciences Stock Up 20.9%

Shares of Integra LifeSciences stock traded up $2.22 during trading hours on Tuesday, reaching $12.87. The company’s stock had a trading volume of 1,048,685 shares, compared to its average volume of 789,664. Integra LifeSciences has a one year low of $8.70 and a one year high of $16.49. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.46 and a current ratio of 2.54. The stock’s fifty day simple moving average is $10.09 and its two-hundred day simple moving average is $11.73. The company has a market capitalization of $1.00 billion, a P/E ratio of -1.90 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The company had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. During the same quarter last year, the company earned $0.41 earnings per share. The company’s revenue for the quarter was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, research analysts forecast that Integra LifeSciences will post 2.34 earnings per share for the current year.

Key Headlines Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Q1 beat on both EPS and revenue — Reported $0.54 EPS vs. $0.41 consensus and revenue $391.9M vs. ~$381.8M consensus; revenue up ~2.4% year‑over‑year, showing underlying demand resilience. GlobeNewswire: Q1 Results
• Positive Sentiment: Raised FY‑2026 EPS guide — Company now targets $2.40–$2.50 vs. street ~2.35, implying confidence in full‑year profitability despite recent volatility. This upgrade helps justify upside in the shares. Zacks: Q1 & Guidance
• Neutral Sentiment: Leadership transition announced — Stuart Essig named President & CEO (Michael McBreen appointed Chief Commercial Officer). Market reaction depends on investor confidence in the new leadership’s strategy and execution. GlobeNewswire: Leadership Transition
• Negative Sentiment: Q2 guidance came in light — Q2 EPS guide of $0.44–$0.52 and revenue $410M–$425M are below consensus (EPS ~$0.53; revenue ~$425.3M), signaling near‑term pressure and creating a mixed read versus the raised full‑year view. That guidance softness likely capped further upside and introduces short‑term uncertainty. Zacks: Beat but Mixed Guidance

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Rubric Capital Management LP lifted its position in shares of Integra LifeSciences by 1.3% during the fourth quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock valued at $96,304,000 after purchasing an additional 100,000 shares in the last quarter. Invesco Ltd. lifted its holdings in Integra LifeSciences by 0.9% during the fourth quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock worth $43,754,000 after acquiring an additional 31,931 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Integra LifeSciences by 9.2% during the third quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock worth $45,634,000 after acquiring an additional 267,134 shares during the period. State Street Corp lifted its holdings in Integra LifeSciences by 0.8% during the fourth quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock worth $34,933,000 after acquiring an additional 21,717 shares during the period. Finally, Paradigm Capital Management Inc. NY lifted its holdings in Integra LifeSciences by 5.3% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 2,664,998 shares of the life sciences company’s stock worth $33,099,000 after acquiring an additional 135,198 shares during the period. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.